Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319364 | PMC |
| http://dx.doi.org/10.1007/s00415-024-12478-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case series.
Ther Adv Neurol Disord
December 2024
Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.
In seropositive myasthenia gravis (MG), complement inhibition has been shown to be an effective and a fast-acting therapeutic option. Myasthenic crisis (MC), usually preceded by impending MC, is a life-threatening complication requiring highly effective treatments with rapid onset of action. Currently used treatment options of MC are limited, consisting mainly of symptomatic and immune therapies, that is, intravenous immunoglobulins and plasma exchange/immunoadsorption.
View Article and Find Full Text PDFMyasthenia gravis: understanding treatment patterns and direct medical costs in the Czech Republic.
Orphanet J Rare Dis
December 2024
Department of Neurology, ERN EURO-NMD Center, University Hospital Brno, Brno, Czech Republic.
Background: Myasthenia gravis (MG) is a rare autoimmune disorder with significant clinical implications, including life-threatening myasthenic crises and exacerbations. Understanding real-world treatment patterns, especially associated direct medical costs, is essential for the effective management of healthcare delivery.
Methods: We conducted a descriptive cohort study using health administrative claims data from the Czech Republic covering more than 1,500 prevalent MG patients.
Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.
Eur J Neurol
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau; and Institut de Recerca Sant Pau, IR-SantPau, Barcelona, Spain.
Article Synopsis
- The study focuses on long-term outcomes and healthcare resource utilization in patients with generalized myasthenia gravis (gMG).
- About 220 patients were analyzed over eight years, showing significant improvement in daily living scores and a reduction in healthcare costs, although some patients continued to experience symptoms and drug-related adverse events.
- The findings suggest that while most patients experience positive outcomes, a minority still suffer from persistent symptoms and side effects, highlighting the ongoing burden of gMG on both patients and healthcare systems.
Rituximab in Refractory Myasthenia Gravis - Challenges and Lessons Learnt.
Ann Indian Acad Neurol
November 2024
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
Nearly 10%-15% patients with generalized myasthenia gravis (MG) have refractory disease and are candidates for newer nonconventional immunotherapies. Rituximab has emerged as an attractive option in them. We describe the efficacy and safety of rituximab in 12 patients with refractory MG treated over a period of 4 years in a tertiary care center.
View Article and Find Full Text PDFComparative Analysis of Intravenous Immunoglobulins (IVIg) vs Plasmapheresis (PLEX) in the Management of Myasthenic Crisis.
Cureus
September 2024
Internal Medicine, FMH College of Medicine & Dentistry, Lahore, PAK.
Article Synopsis
- Myasthenia gravis (MG) is a disease that makes muscles weak and can lead to a serious problem called myasthenic crisis, which affects breathing.
- Two treatments for this crisis are intravenous immunoglobulins (IVIg) and plasmapheresis (PLEX), but it's hard to determine which one works better.
- The choice of treatment depends on the patient's situation, available resources, and doctor's opinion, and more research is needed to create clear guidelines for helping patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!